Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

China Medicine Raises $69.6 Million in PE from JPMorgan Chase

publication date: Jan 7, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China Medicine Corporation signed a deal that raises $69.6 million in new capital from One Equity Partners, the private equity investment subsidiary of JPMorgan Chase & Co. It is the first investment for One Equity Partners in China. China Medicine will use the first portion of the money to complete its $21.5 million acquisition of Guangzhou LifeTech Pharma, a transaction that helps move China Medicine from a distribution company into an integrated company with its own drugs to sell. More details...

Stock Symbol: (OTCBB: CHME)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...